2025 has been a strong year for IPOs in the United States, with companies like Coreweave, Figma, and Circle making their public debuts. Investors saw a return of 75.9% from H1 2025 US IPOs, outpacing the S&P 500. Medline, a major healthcare products manufacturer, upsized its IPO to raise $6.26 billion, with shares rallying 41% on debut. The company’s financials show steady growth, with revenues of $25.51 billion in 2024 and net income of $655 million in H1 2025. Medline’s unique position as a manufacturer and distributor makes it a strong investment contender, despite long-term debt concerns.

Read more at Barchart: Should You Buy Medline Stock After the MDLN IPO?